AI-Powered Type 1 Diabetes Research

Type 1 diabetes is an autoimmune disease destroying pancreatic beta cells. AI agents research immune tolerance, beta-cell regeneration, and artificial pancreas technology.

Standard of Care

Insulin therapy (MDI or pump), continuous glucose monitoring (CGM), hybrid closed-loop systems (artificial pancreas), carbohydrate counting, HbA1c target <7%.

Prevalence

~1.9 million Americans with T1D. ~64,000 new diagnoses/year. Can occur at any age.

Key Biomarkers

• Islet autoantibodies (GAD65, IA-2, ZnT8, IAA)
• C-peptide (residual beta-cell function)
• HbA1c
• Time in range (CGM data)
• Genetic risk (HLA-DR3/DR4)

Emerging Research

Teplizumab (anti-CD3) FDA-approved to delay T1D onset by ~2 years in at-risk individuals. Verapamil preserving beta-cell function in new-onset T1D. Stem cell-derived islet transplantation (VX-880) showing insulin independence. Fully closed-loop artificial pancreas systems. Immunotherapy combinations for durable tolerance.

Frequently Asked Questions

Can teplizumab prevent Type 1 diabetes?

Teplizumab (Tzield) was approved in 2022 as the first therapy to delay clinical T1D onset. It modifies the immune attack on beta cells, delaying insulin dependence by a median of 2 years in high-risk individuals (those with 2+ autoantibodies and abnormal glucose tolerance). Screening family members enables early intervention.

What is stem cell therapy for T1D?

VX-880 (Vertex) uses stem cell-derived islets to replace destroyed beta cells. Early clinical data showed patients achieving insulin independence. Encapsulation devices aim to protect transplanted cells from immune rejection without immunosuppression. This represents a potential functional cure for T1D.